Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...
Number 5: The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the ...
The biosimilar landscape continues to expand, with 2024 delivering a wave of exciting approvals across multiple therapeutic areas. Last year alone saw the FDA green light some firsts for biosimilars ...